Roivant Sciences vs Abcellera Biologics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Roivant Sciences Ltd (ROIV)

Q3 202617 Jun – 9 Sep 2026

▲4

Roivant's Cash, Patent Wins, and Drug Approvals Drive Record High

Cash and Moderna Settlement Roivant ended fiscal 2026 with $4.3 billion in cash and a $2.25 billion settlement from Moderna over patent litigation. This huge cash pile gives Roivant the financial firepower to fund its drug pipeline and return value to shareholders, supporting the stock price.
This is a major new financial event that strengthens the balance sheet and reduces risk.
New Patent Lawsuits Against Pfizer and BioNTech Roivant's subsidiary Genevant filed new patent lawsuits against Pfizer and BioNTech over COVID vaccine technology, seeking injunctions and damages. If successful, these could bring in more settlement money like the Moderna deal, adding potential upside to ROIV shares.
This is a new legal action that could lead to future cash inflows, directly affecting ROIV's value.
FDA Approval and Launch of Lisraya The FDA approved Priovant's Lisraya for dermatomyositis, and it launched at $35,000 per month. As the first targeted therapy for a rare disease, it could generate significant revenue, though adoption may be gradual due to the high price and small patient pool.
This is a new product approval and launch, a key commercial milestone that drives future revenue.
Positive Lung Disease Trial Results Roivant's drug mosliciguat met its primary endpoint in a phase 2 trial for pulmonary hypertension with interstitial lung disease, sending the stock to an all-time high. This success opens a large market opportunity and validates Roivant's pipeline, boosting investor confidence.
This is a new clinical win that directly caused a major stock rally and highlights future growth potential.

July 202617 Jun – 9 Sep 2026

▲4

Roivant's Cash, Patent Wins, and Drug Approvals Drive Record High

Cash and Moderna Settlement Roivant ended fiscal 2026 with $4.3 billion in cash and a $2.25 billion settlement from Moderna over patent litigation. This huge cash pile gives Roivant the financial firepower to fund its drug pipeline and return value to shareholders, supporting the stock price.
This is a major new financial event that strengthens the balance sheet and reduces risk.
New Patent Lawsuits Against Pfizer and BioNTech Roivant's subsidiary Genevant filed new patent lawsuits against Pfizer and BioNTech over COVID vaccine technology, seeking injunctions and damages. If successful, these could bring in more settlement money like the Moderna deal, adding potential upside to ROIV shares.
This is a new legal action that could lead to future cash inflows, directly affecting ROIV's value.
FDA Approval and Launch of Lisraya The FDA approved Priovant's Lisraya for dermatomyositis, and it launched at $35,000 per month. As the first targeted therapy for a rare disease, it could generate significant revenue, though adoption may be gradual due to the high price and small patient pool.
This is a new product approval and launch, a key commercial milestone that drives future revenue.
Positive Lung Disease Trial Results Roivant's drug mosliciguat met its primary endpoint in a phase 2 trial for pulmonary hypertension with interstitial lung disease, sending the stock to an all-time high. This success opens a large market opportunity and validates Roivant's pipeline, boosting investor confidence.
This is a new clinical win that directly caused a major stock rally and highlights future growth potential.

Latest17 Jun – 9 Sep 2026

▲4

Roivant's Cash, Patent Wins, and Drug Approvals Drive Record High

Cash and Moderna Settlement Roivant ended fiscal 2026 with $4.3 billion in cash and a $2.25 billion settlement from Moderna over patent litigation. This huge cash pile gives Roivant the financial firepower to fund its drug pipeline and return value to shareholders, supporting the stock price.
This is a major new financial event that strengthens the balance sheet and reduces risk.
New Patent Lawsuits Against Pfizer and BioNTech Roivant's subsidiary Genevant filed new patent lawsuits against Pfizer and BioNTech over COVID vaccine technology, seeking injunctions and damages. If successful, these could bring in more settlement money like the Moderna deal, adding potential upside to ROIV shares.
This is a new legal action that could lead to future cash inflows, directly affecting ROIV's value.
FDA Approval and Launch of Lisraya The FDA approved Priovant's Lisraya for dermatomyositis, and it launched at $35,000 per month. As the first targeted therapy for a rare disease, it could generate significant revenue, though adoption may be gradual due to the high price and small patient pool.
This is a new product approval and launch, a key commercial milestone that drives future revenue.
Positive Lung Disease Trial Results Roivant's drug mosliciguat met its primary endpoint in a phase 2 trial for pulmonary hypertension with interstitial lung disease, sending the stock to an all-time high. This success opens a large market opportunity and validates Roivant's pipeline, boosting investor confidence.
This is a new clinical win that directly caused a major stock rally and highlights future growth potential.

Abcellera Biologics Inc (ABCL)

Q3 202617 Jun – 11 Aug 2026

▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.
This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.
Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.
This is a new financial report showing deteriorating results, which weighs on the stock price.
ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.
This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

July 202617 Jun – 11 Aug 2026

▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.
This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.
Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.
This is a new financial report showing deteriorating results, which weighs on the stock price.
ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.
This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

Latest17 Jun – 11 Aug 2026

▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.
This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.
Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.
This is a new financial report showing deteriorating results, which weighs on the stock price.
ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.
This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.